Seres Therapeutics (NASDAQ:MCRB – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Institutional and Insider Ownership
59.3% of Seres Therapeutics shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Seres Therapeutics and MDxHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Seres Therapeutics | -1,192.94% | -114.82% | -34.15% |
| MDxHealth | -33.46% | N/A | -24.25% |
Earnings & Valuation
This table compares Seres Therapeutics and MDxHealth”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Seres Therapeutics | $790,000.00 | 27.10 | $5.70 million | ($2.43) | -0.88 |
| MDxHealth | $107.88 million | 0.08 | -$33.52 million | ($0.72) | -0.26 |
Seres Therapeutics has higher earnings, but lower revenue than MDxHealth. Seres Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Seres Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Seres Therapeutics and MDxHealth, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Seres Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| MDxHealth | 1 | 4 | 1 | 0 | 2.00 |
Seres Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 698.12%. MDxHealth has a consensus price target of $1.33, indicating a potential upside of 624.64%. Given Seres Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than MDxHealth.
Summary
Seres Therapeutics beats MDxHealth on 7 of the 13 factors compared between the two stocks.
About Seres Therapeutics
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
